分享 收藏

Recombinant Human IP-10/CXCL10

品牌：翌圣生物
產(chǎn)地：
供應(yīng)商報(bào)價(jià)：面議

翌圣生物科技(上海)股份有限公司更新時(shí)間：2024-12-24 09:03:45

銷售范圍售全國

入駐年限第1年

營業(yè)執(zhí)照已審核

同類產(chǎn)品趨化因子(83件)

立即掃碼咨詢

聯(lián)系方式：400-611-1883

聯(lián)系我們時(shí)請(qǐng)說明在儀器網(wǎng)（www.vietnamtrade.org）上看到的!

掃碼分享

為您推薦

詳細(xì)介紹

(C-X-C motif) ligand (CXCL)10 (CXCL10), also known as IP-10, belongs to the ELR(-) CXC subfamily chemokine. CXCL10 was originally identified as an IFN-gamma -inducible gene in monocytes, fibroblasts and endothelial cells. It has since been shown that CXCL10 mRNA is also induced by LPS, IL-1 beta, TNF alpha, IL-12 and viruses. CXCL10 was originally identified as an IFN-gamma -inducible gene in monocytes, fibroblasts and endothelial cells. CXCL10/IP-10 exerts its function through binding to chemokine (C-X-C motif) receptor 3 (CXCR3), a seven trans-membrane receptor coupled to G proteins. CXCL10/IP-10 and its receptor, CXCR3, appear to contribute to the pathogenesis of many autoimmune diseases, organ specific (such as type 1 diabetes, autoimmune thyroiditis, Graves' disease and ophthalmopathy), or systemic (such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, mixed cryoglobulinemia, Sjögren syndrome, or systemic sclerosis). In adition, CXCL10 has been reported to be a potent inhibitor of angiogenesis and to display a potent thymus-dependent antitumor effect.

Product Properties

Synonyms	Gamma-IP10, Small-inducible Cytokine B10
Accession	P02778
GeneID	3627
Source	E.coli-derived Human IP-10/CXCL10, Val22-Pro98.
Molecular Weight	Approximately 8.6 kDa.
AA Sequence	VPLSRTVRCT CISISNQPVN PRSLEKLEII PASQFCPRVE IIATMKKKGE KRCLNPESKA IKNLLKAVSK EMSKRSP
Tag	None
Physical Appearance	Sterile Filtered White lyophilized (freeze-dried) powder.
Purity	> 97% by SDS-PAGE and HPLC analyses.
Biological Activity	The biological activity determined by a chemotaxis bioassay using human peripheral blood T-lymphocytes is in a concentration range of 10-50 ng/mL. Fully biologically active when compared to standard.
Endotoxin	< 1.0 EU per 1μg of the protein by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered concentrated solution in 20 mM PB, pH 7.4, 50 mM NaCl.
Reconstitution	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.